natgillin/translations-raw huggingface dataset:
A compound of formula (I) or a pharmaceutically acceptable salt thereof for use according to any one of claims 1 to 3 wherein R6 is hydroxy or C1-6 alkyl optionally substituted by piperidinyl, piperazinyl, morpholinyl, homomorpholinyl or homopiperazinyl. 
Spoj formule (I) prema zahtjevima 1 do 3, naznačen time da je R* hidroksi ili C,4 alkil opcionalno supstituiran piperidinilom, piperazinilom, morfolinilom, homomorfolinilom ili homopiperazinilom.
A pharmaceutical composition adapted for administration to the stomach of a patient comprising an effective amount of at least one pharmaceutically acceptable zinc salt in combination with an effective amount of an anti-H. pylori agent, optionally in combination with a pharmaceutically acceptable carrier, additive or excipient for use to rapidly increase the pH of the gastric juices in the stomach of a patient in need thereof to at least 3.0 within a period no greater than one hour after administration. 
HR P20151437 T1 PATENTNI ZAHTJEVI Farmaceutski pripravak za primjenu u želudac bolesnika, koji sadrži učinkovitu količinu barem jedne farmaceutski prikladne cinkove soli u kombinaciji s inhibitorom protonske pumpe, po izboru u kombinaciji s farmaceutski prikladnim nosačem, aditivom ili pomoćnom tvari za uporabu za brzo povećanje pH želučanih sokova u želucu bolesnika kojemu je to potrebno na barem 3.0 u vremenu ne većem od jednog sata nakon primjene.
A mouse comprising: 
Miš koji sadrži:
dissolving rifaximin in diethylene glycol monoethyl ether (DEGME), in a DEGME-:-rifaximin molar ratio ranging from 4:1 to 500:1, at temperatures ranging from room temperature to 100°C, for a duration of time ranging from 5 minutes to 5 hours to obtain a rifaximin solution; 
- > dodavanja dietilen-glikol-monoetil-etera rifaksiminu, u molarnom omjeru u rasponu od 10:1 do 100:1, na temperaturama u rasponu od sobne temperature do 100 "C u trajanju u rasponu od 5 minuta do 5 sati kako bi se dobilo otopinu rifaksimina; -
Samples were prepared as follows: An amount of material equivalent to 100 mg solids was transferred into a 100-ml volumetric flask with the aid of water, followed by dilution to volume, stirring and centrifuging if the solution is cloudy. 
Uzorci su pripremljeni kako slijedi: Količina materijala ekvivalentna 100 mg čvrste tvari je prenesena u 100 mL volumetrijsku tikvicu uz pomoć vode, zatim razrijeđena do volumena, pomiješana i centrifugirana ako je otopina bila zamućena.
The titled compound was prepared analogously to 4-cyano-3-ethoxy-benzenesulfonyl chloride (Intermediate 127c) by replacing 2-ethoxy-4-nitro-benzonitrile with 2-methyl-4-nitro-benzonitrile. 
Naslovni spoj je proizveden analogno 4-cijano-3-etoksi-benzensulfonil kloridu (intermedijat 127c) zamjenom 2-etoksi-4-nitro-benzonitrila s 2-metil-4-nitrobenzo-nitrilom.
Step 1 of producing an amorphous composite from 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzoazepine and/or a salt thereof, and hydroxypropylcellulose containing a hydroxypropoxyl group in an amount of 50 wt.% or greater; 
Koraka 1 = dobivanja amorfne smjese iz 7-klor-5-hidroksi-1-[2-metil-4-(2-metilbenzoilamino)benzoill-2,3,4,5-tetrahidro-1H-benzoazepina i/ili njegove soli i hidroksipropilceluloze koja sadrži hidroksipropoksilnu skupinu u količini od 50 %, težinski, ili većoj;
The antibody drug conjugate of any one of claims 1-5, 12 or 13, wherein the anti-DLL3 antibody comprises residues 30-36 of SEQ ID NO: 84 for CDR-L1, residues 46-55 of SEQ ID NO: 84 for CDR-L2, residues 89-96 of SEQ ID NO: 84 for CDR-L3, residues 30-35 of SEQ ID NO: 85 for CDR-H1, residues 47-58 of SEQ ID NO: 85 for CDR-H2 and residues 93-101 of SEQ ID NO: 85 for CDR-H3, wherein the residues are numbered according to MacCallum. 
Konjugat protutijelo-lijek prema bilo kojem od zahtjeva 1 do 5, 12 ili 13, naznačen time, da protutijelo anti-DLL3 obuhvaća ostatke od 30 do 36 od SEQ ID NO:84 za CDR-LI, ostatke od 46 do 55 od SEQ ID NO:84 za CDR-L2, ostatke od 89 do 96 od SEQ ID NO:84 za CDR-L3, ostatke od 30 do 35 od SEQ ID NO:85 za CDR-HI, ostatke od 47 do 58 od SEQ ID NO:85 za CDR-H2 i ostatke od 93 do 101 od SEQ ID NO:85 za CDR-H3, pri čemu su ostatci HR P20171549 T1 numerirani prema sustavu MacCallum.
The topical veterinary composition of claim 7, wherein the at least second active agent is an avermectin or milbemycin. 
Topikalni veterinarski pripravak prema zahtjevu 8, naznačen time, da najmanje druga djelatna tvar je regulator rasta kukaca.
As shown, the back edge is displaced inwards towards to internal area of each two side of the inner part so that the back part 71 be on level with the outermost edge 73 of the back side of the packaging when the packaging is closed. 
HR P20060319 T3 prostora svake od dviju strana unutarnjeg dijela, tako da stražnji dio 71 bude na nivou s najisturenijim rubom 73 stražnje strane pakiranja, kada je pakiranje zatvoreno.
The method according to embodiment 23, wherein the a-synuclein disorder is Parkinson's disease. 
Lijek za uporabu prema zahtjevu 1 ili 2, pri čemu je poremećaj vezan uz a-sinuklein Parkinsonova bolest.
An antibody, or a derived compound or functional fragment of same, according to claim 6, characterized in that it comprises a light chain comprising the CDR-L1 of the sequence SEQ ID No. 9, the CDR-L2 of the sequence SEQ ID No. 10 and the CDR-L3 of the sequence SEQ ID No. 3. 
– laki lanac koji prema Kabat sadrži CDR-L1 sekvencije SEQ ID No. 9, CDR-L2 sekvencije SEQ ID No. 10 te CDR-L3 sekvencije SEQ ID No. 3, te – teški lanac lanac koji prema Kabat sadrži CDR-H1 sekvencije SEQ ID No. 11, CDR-H2 sekvencije SEQ ID No. 12 te CDR-H3 sekvencije SEQ ID No. 6,
combining the materials of steps a), b) and optionally c), thereby providing a first combinatorial material; fermenting the first combinatorial material of step d) using the inoculum of step a) for a period of 3-10 days; thereby providing a first fermented composition; 
fermentiranje prvog kombinatornog materijala iz koraka d) primjenom cjepiva iz koraka a) pri temperaturi u rasponu 15-45° C i tijekom perioda u rasponu 2-40 dana; na taj način dobiva se prvi fermentirani sastav;
The method according to any one of claims 1 to 8, wherein the one or more cells is cultured in at least 100 L of the supplemented basal cell culture media. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što se jednu ili više stanica uzgaja u najmanje 100 1 kompletiranog osnovnog medija za uzgoj stanica.
The said fluid comprising a liquid or liquid mixture, a suspension, dispersion or an emulsion, and wherein said liquid or liquid mixture, suspension dispersion or emulsion is a crop- or plant protectant or fertilizer. The present invention further concerns a process for micronizing a fluid, wherein the fluid is a fire extinguishing agent. 
Postupak prema zahtjevu 27, naznačen time da fluid sadrži tekućinu ili tekuću smjesu, suspenziju, disperziju ili emulziju. Postupak prema zahtjevu 28, naznačen time da tekućina ili tekuća smjesa je zaštitno sredstvo za usjeve ili biljke 1li gnojivo. Postupak prema zahtjevu 28, naznačen time da fluid je sredstvo za gašenje požara.
providing an odorising apparatus (10) suitable for producing and dispensing an odorising/aromatising substance (G1+G2+L, OD) in gaseous form in the packaging (CON) containing the product (PR), before the packaging is hermetically sealed, 
i = raspršivanje odorizirajuće/aromatizirajuće supstance (G1+G2+L, OD) u plinovitom stanju u pakiranje (CON) koje sadrži proizvod (PR), prije hermetičkog zatvaranja pakiranja, gdje rečeni uređaj za odorizaciju (10) sadrži:
A compound of formula (I): 
Spoj sa formulom (1):
The method according to claim 1, wherein the data concerning the blood contained in the bag are used to arrange the bags inside said apparatus in accordance with blood type, expiry date, destination and intended use of the blood. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 7, kod kojega se podaci koji se odnose na krv koja je sadržana u vrećici koriste za raspoređivanje vrećica unutar uređaja (1) u skladu s krvnom grupom, datumom isteka roka valjanosti, odredištem i namjenom korištenja krvi.
Alternatively or additionally to the described chemical or temperature dependent methods, other phenomens can be used for filling. 
Alternativno ili dodatno uz opisane kemikalije ili postupke ovisne o temperaturi, za punjenje se mogu primijeniti i druge pojave.
A compound, pharmaceutically acceptable salt thereof or composition according to claim 6, for use in treatment of pseudobulbar affect. 
Tvar, njena farmaceutski prihvatljiva sol ili sastav prema patentnom zahtjevu 9, za uporabu u liječenju pseudobulbarnog afekta.
Stirred at 60 °C for 96h, then HCl (16 mmol) and water (20 mL) was added. 
Miješa se na 60 "C kroz 96 sati, te se doda HCI (16 mmol) i voda (20 ml).
Process for synthesizing compounds of claim 1, comprising the reaction between a compound of formula II as in claim 14, with a compound of formula VIII wherein 
Postupak sinteze spojeva u skladu s patentnim zahtjevom 1, naznačen time što se sastoji u reakciji između spoja formule II u skladu s patentnim zahtjevom 14 i spoja formule VIII R14
A compound represented by the following general formula (1) or a salt thereof; 
PATENTNI ZAHTJEVI Spoj predstavljen sljedećom općom formulom (1) ili njegove soli;
Anti-Adrenomedullin (ADM) antibody or an anti-ADM antibody fragment binding to adrenomedullin or anti-ADM non-Ig scaffold binding to adrenomedullin 
Anti-Adrenomedulin (ADM) antitijelo ili fragment anti-ADM antitijela koji se veže na adrenomedulin ili anti-ADM non-Ig skela koja se veže na adrenomedulin
at least 45% of the cells in the population express detectable levels of CD178 (FAS ligand), 
(ili) najmanje 45 % stanica u populaciji na svojoj površini izražava uočljive razine CD178 (FAS ligand),
The apparatus of claim 18 wherein the conduit is made of plastic. 
Sustav prema zahtjevu 23, naznačen time što je cjevovod napravljen od plastike.
Use of the antibodies according to any of claims 1 to 4 or in form of a pharmaceutical composition according to claim 11 comprising PRLR antibodies or antigen-binding fragment according to any of claims 1 to 4 in preparation of a pharmaceutical formulation for parenteral administration, whereby methods of parenteral delivery include topical, intra-arterial, intramuscular, subcutaneous, intramedullary, intrathecal, intraventricular, intravenous, intraperitoneal, intrauterine, vaginal, or intranasal administration. 
Farmaceutski pripravak prema zahtjevu 14 koji sadrži PRLR antitijela ili fragment koji veže antigene ili njihove sazrele varijante prema bilo kojem od zahtjeva 1 do 4, naznačen time da je za uporabu putem parenteralno davanje, pri čemu postupci parenteralne primjene uključuju lokalnu, intraarterijsku, intramuskularnu, potkožnu, intramedulamu, intratekalnu, intraventrikularnu, intravenoznu, intraperitonealnu, intrauterinu, vaginalnu, ili intranazalnu primjenu.
Method of preparing a salt of rasagiline according to any of claims 1-4, which comprises the steps of mixing rasagiline and the acid and recovering the salt. 
Postupak za pripremu soli rasagilina prema bilo kojem od patentnih zahtjeva 1-4, naznačen time, da obuhvaća stupnjeve miješanja rasagilina 1 kiseline, te dobivanje soli.
In one embodiment of the present invention is a synthetic process for the preparation of novel tetrazoles of Formula (I). 
Sinteza spojeva Formule (I) Ovdje su također opisani postupci sinteze za pripremu novih tetrazola Formule (I).
Use according to article 2, wherein the infection is a viral infection, such as Human Immunodefiency Virus (HIV), Herpes Simplex Virus (HSV), Human Papilloma Virus (HPV). 
Jedan ili više oligomera mliječne kiseline za uporabu prema patentnom zahtjevu 6, pri čemu je virusna infekcija odabrana od Virusa Humane Imunodeficijencije (HIV), Virusa Herpes Simpleks (HSV), Humanog Papiloma Virusa (HPV).
where in each peptide monomer of the peptide dimer, each amino acid is indicated by standard one letter abbreviation, AcG is N-acetylglycine, 1-nal is 1-naphthylalanine, and MeG is N-methylglycine; 
(i) u svakom peptidnom monomeru peptidnog dimera svaka aminokiselina je označena standardnom jednoslovnom kraticom, AcG je N-acilglicin, 1-nal je 1-naftilalanin, a MEG je N-metilglicin;
The compound or salt of claim 50 wherein said autoimmune disease is bullous skin disorder. 
Spoj ili sol prema zahtjevu 50 naznačen time da navedena autoimuna bolest je bulozni kožni poremećaj.
and R2 together with the nitrogen atom to which they are attached form a 4- to 7-membered N-heterocycle, where the N-heterocycle may be substituted by 1 to 3 substituents independently of one another selected from the group consisting of oxo, hydroxy, monofluoromethyl, difluoromethyl, trifluoromethyl, hydroxycarbonyl, tert-butoxycarbonyl, aminocarbonyl, C1-C4-alkyl, C1-C4-alkoxy, C1-C4-alkoxy-C1-C4-alkyl, halogen and hydroxyalkyl, 
R! i R* zajedno s dušikovim atomom na koji su oni vezani tvore 4- do 7-člani N-heterocikl, gdje N-heterocikl može biti supstituiran s 1 do 3 supstituenta koji su međusobno neovisno odabrani iz skupine koja sadrži okso, hidroksi, monofluorometil, difluorometil, trifluorometil, -hidroksikarbonil, tertbutoksikarbonil, aminokarbonil, C;-Ca-alkil, Ci-C4-alkoksi, C1-C4-alkoksi-C;-C,-alkil, halogen i hidroksialkil, ili gdje N-heterocikl može imati dva supstituenta koji, zajedno s ugljikovim atomom iz N-heterocikla na koji su oni zajednički vezani, tvore 4- do 6-člani heterociki, gdje ovaj heterocikl sa svoje strane može biti supstituiran s 1 do 3 supstituenta koji su međusobno neovisno odabrani iz skupine koja sadrži okso, metil i etil,
The compound according to claim 1, wherein the compound has formula I-C 
Spoj prema patentnom zahtjevu 1, pri čemu je spoj formule I-C
A method according to claim 13 wherein the T-cell response to said composition is measured by contacting the composition with T cells in a sample taken from the subject, under conditions which allow the composition and the T cells to interact; and determining whether or not any of the T cells are stimulated; and thereby determining whether or not a T-cell response is present or absent. 
Metoda u skladu sa zahtjevom 13, naznačena time, što odgovor T-stanice sa navedenim sastavom je mjeren pomoću kontaktiranja sastava sa T stanicama u uzorku izabranom iz predmeta, pod uvjetima koji omogućuju sastav i T stanice na interakciju, te utvrđivanje da li je ili nije bilo koji od T stanica stimuliran; čime bi se utvrdilo da li je ili nije odgovor T-stanice prisutan ili odsutan.
Further embodiments of the invention relate to: A process of preparing a solid oral extended release pharmaceutical dosage form, comprising at least the steps of: 
L Postupak pripreme oralnog farmaceutskog oblika davanja s produljenim otpuštanjem u krutom stanju, koji sadrži barem sljedeće korake:
In some embodiments, the aminooxy compound is chosen from compounds of Formula II: wherein Y is the second reactive group, Z is chosen from alkyl, alkenyl, alkynyl, heteroaryl, aryl, and heterocyclyl, and P is chosen from amino protecting groups. 
2. = Postupak prema patentnom zahtjevu 1, naznačen time što je aminooksi spoj odabran od spojeva s Formulom II: e P H Formula Il pri čemu Y je druga reaktivna skupina, Z je odabran od alkila, alkenila, alkinila, heteroarila, arila, i heterociklila, 1 15
FIG. 4 b shows that again, the design engraved in the plate has been transferred to the soft-magnetic ink patch; the latter shows a 3-dimensional effect and a seems to move when the print is looked at from different angles. 
Slika 4b prikazuje kako je uzorak ugraviran u ploču ponovo prenesen na otisak meko magnetne tinte; potonju odlikuje 3-dimenzionalni učinak, a kada se otisak gleda iz različitih kuteva čini se kako se kreće.
An isolated two-chain polypeptide comprising an amino acid sequence having at least 80% homology to SEQ ID NO.13, wherein the polypeptide: 
Dvolančani polipeptid pogodan za uporabu u parenteralnoj primjeni naznačen time što sadrži aminokiselinsku sekvencu koja ima najmanje 80% homologije sa SEQ ID NO.13, pri čemu polipeptid:
The method of claim 14, wherein an amount of the plasticizer is from 1 part by weight to 10 parts by weight based on 100 parts by weight of the cellulose ether. 
Metoda iz patentnog zahtjeva 11, gdje je količina plastifikatora od 1 dijela po masi do 10 dijelova po masi bazirano na 100 dijelova po masi celuloznog etera.
The polystyrene of claim 1, wherein the polystyrene comprises struts and cell walls, and wherein the struts and cell walls comprise alumina. 
Polistiren sukladno zahtjevu 1, naznačeno time da polistiren sadrži potpornje i ćelijske zidove, i naznačeno time da potpornji i ćelijski zidovi sadrže aluminijev oksid.
Preferably, the grooves extend along the entire length of the hinges so that the protrusions 80 may extend along the entire length of the edge of the outer parts and/or metal layer/part which reinforces said parts. As seen in FIG. 
Poželjno je da se utori prostiru duž cijele dužine panta, tako da se izbočenja 80 mogu protezati duž cijele dužine ruba vanjskih dijelova i/ili metalnog sloja/dijela koji pojačava navedene dijelove.
is H or C1-4alkyl, or an enantiomer thereof, a prodrug thereof or a pharmaceutically acceptable salt thereof. 
ili njegov enantiomer, njegov prolijek ili njegova farmaceutski prihvatljiva sol, gdje su prolijekovi odabrani od:
The pharmaceutical composition of 41, further comprising an immunosuppressive or anti-inflammatory agent. 
Farmaceutska smjesa iz Zahtjeva 17, naznačena time, što dalje sadrži imunosupresivno ili antiupalno sredstvo.
A liquid pharmaceutical formulation of an anti-human PD-1 antibody, or antigen binding fragment thereof comprising: 
Stabilna tekuća farmaceutska formulacija anti-humanog PD-1 antitijela, koja sadrži:
at least one memory for storing successive rows of data, each comprising the fuel level data, the time and date data, and the geolocation data at a given time, with a periodicity in the range 1 s to 240 s; 
- barem jednu memoriju (106) za pohranu uzastopnih redova podataka (Lpyg), koji svaki sadrži podatke o razini goriva, podatke o zabilježenom vremenu, te geolokacijskih podataka u danom vremenu, uz periodičnost između 1 i 240 sekundi;
The use of any one of the preceding claims, wherein the gene encodes a therapeutic protein selected from growth factors, cytokines, hormones, neurotransmitters, enzymes, anti-apoptotic factors, angiogenic factors, and any protein known to be mutated in pathological disorders such as the "survival of motor neuron" protein (SMN). 
AAV genom bez funkcionalnih Rep i Cap kodirajućih virusnih sljedova. AAV vektor 1z bilo kojeg od prethodnih patentnih zahtjeva, pri čemu gen kodira terapijsku RNA, ili terapijski protein odabran između čimbenika rasta, citokina, hormona, neurotransmitera, enzima, antiapoptotičkih čimbenika, angiogenih čimbenika 1 proteina, preživljavanja motoričkih neurona" (SMN).
Recess 34 may be an aperture that extends through the thickness of the key 22 . 
Å upljina 34 može biti otvor koji se pruža kroz debljinu ključa 22.
The method according to any one of claims 1-9 characterized in, that the method further comprises adding a nutrient solution containing at least one dissolved nitrogen-containing, one phosphorous-containing or one potassium-containing species to the said contaminated subsurface environment prior to, during, or after the said re-introduction of the enriched culture. 
Metoda prema bilo kojem od zahtjeva 1-15, naznačena time da ta metoda nadalje uključuje dodavanje jedne hranjive otopine koja sadrži najmanje jednu otopljenu svojtu koja sadrži dušik, jednu koja sadrži fosfor ili jednu koja sadrži kalij, u spomenuti zagađeni podzemni okoliš prije ili tijekom ili nakon spomenutog ponovnog vraćanja obogaćene mikrobne zajednice u taj okoliš.
applying a solution comprising the antibody of the IgG class to the equilibrated cation exchange chromatography material thereby loading the chromatography material, and 
- < nanošenje otopine koja sadrži protutijelo IgG-razreda na uravnoteženi kromatografski materijal, te time punjenje materijala za kromatografiju,
a tableting aid comprising magnesium stearate and microcrystalline cellulose. 
(B)pomoćno sredstvo za tabletiranje, koje obuhvaća magnezijev stearat i mikrokristaličnu celulozu.
The process according to claim 23, characterized in that said surface of the sanitary is wet following a discharge of water effected before the application of the composition. 
Postupak prema zahtjevu 23, naznačen time što je površina sanitarije mokra nakon ispuštanja vode prije nanošenja sredstva.
In a preferred embodiment, the second piece of fabric is secured to the first piece of fabric along a few transverse connection lines extending parallel to the longitudinal direction of the coil spring, said connecting lines preferably consisting of a surface joint, such an adhesive, a weld or the like. 
Pojedinačno ušivena spiralna opruga (2) iz Zahtjeva 3, pri čemu je drugi dio tkanine pričvršćen za prvi dio tkanine duž nekoliko transverzalnih poveznica (33) koje se pružaju paralelno longitudinalnom smjeru spiralne opruge (4), navedene poveznice po mogućnosti sadrže površinsko vezivo, poput ljepila, zavarivanja ili sličnog.
Even if it could work as a closed system, the apparatus 1 according to the present invention is typically placed in a hospital or the like, where it is able to be connected to the management-system of the hospital and, in other words, have the program 18 of the apparatus 1 communicate with the hospital management program 17 (see FIG. 3). 
Kad bi čak i mogao raditi kao zatvoreni sustav, uređaj 1 koji je u skladu s predmetnim izumom tipično je smješten u bolnici ili negdje slično tome, gdje on može biti spojen na sustav za upravljanje bolnicom, drugim riječima, da ima program 18 uređaja 1 koji je povezan s programom upravljanja bolnicom 17 (vidi sliku 3).
an inserter (1905-L1) configured to insert an layer 1 header into the time-interleaved constellation values corresponding to the L1 signaling data, wherein the Layer 1 header includes the L1 TI mode information and L1 INFO SIZE information for indicating the half size of the L1 signaling data and Layer 1 block padding data; 
PATENTNI ZAHTJEVI Prijenosnik za prijenos emitiranog podatka do prijamnika, prijenosnik obuhvaća: prednje ispravljanje pogreške, koder (702-L1) konfiguriran za kodiranje signalnog podatka razine 1, navedenog kao signalni podatak L1 dio za umetanje bitova (703-L1) konfiguriran za umetanje bitova u kodirani signalni podatak L1;
Table 5 summarizes the chromatography results. 
U Tablici 1 prikazani su sumarni rezultati kromatografije.
The system of claim 1 wherein the drive means are further configured to provide a drive signal such that the first frequency and the second frequency overlap. 
Sustav prema bilo kojem od zahtjeva 1 do 3, naznačen time, da je sustav namješten tako da se primarni pokretački signal i sekundarni pokretački signal preklapaju.
Furthermore, mixtures of the aforementioned acids can be used. Typically the antagonist of M3 muscarinic receptors is 3(R)-(2-Hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide. 
Kombinacija sukladno patentnom zahtjevu 1, naznačena time, da je antagonist M3 muskarinskog receptora (b) spoj 3(R)-(2-hidroksi-2,2-ditien-2-ilacetoksi)-1-(3-fenoksipropil)-1-azoniabiciklo[2.2.2 |oktanbromid.
In the embodiment described here, the third metallic layer 13 is advantageously made of aluminum powder. 
U ovdje opisanoj izvedbi, treći metalni sloj 13 je korisno izrađen od aluminijskog praha.
Compounds of general formula I according to claim 1, wherein, R1 and R2 are independently of one another hydrogen, fluorine, chlorine, a methoxy group, 
Spojevi s općom formulom I [image] naznačeni time da i R2 su međusobno neovisno vodik, fluor, klor, metoksi skupina;
reacting Compound (C) with diphenylphosphoryl azide and then with benzyl alcohol to form Compound (D) 
(e) reakciji Spoja (C) s difenilfosforil-azidom, a zatim s benzil-alkoholom kako bi se dobilo Spoj (D)